Ocuphire Pharma awards director Dr. Pepose $39,583/mo consulting fee, 32K RSUs and 48K options at $1.79

Opus Genetics, Inc.

Monthly consulting fee of $39,583 for Dr. Jay Pepose, an existing director, effective April 11, 2024.
Grant of 32,000 restricted stock units vesting on April 11, 2025, subject to continued service.
Options to purchase 48,000 shares at $1.79 (closing price on grant date), vesting in 12 monthly installments.
Agreement terminates on April 11, 2025, unless extended by mutual written agreement.
Consulting services in the field of ophthalmology; Dr. Pepose remains an independent contractor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.